Groups Urge Federal Action Against Eclipse Cigarettes

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 5
Volume 10
Issue 5

WASHINGTON-Twenty-two public health organizations have again called on the federal government to initiate action against R.J. Reynolds Co. to stop it from making unsubstantiated health-related claims about its Eclipse cigarette.

WASHINGTON—Twenty-two public health organizations have again called on the federal government to initiate action against R.J. Reynolds Co. to stop it from making unsubstantiated health-related claims about its Eclipse cigarette.

In separate letters to the Department of Health and Human Services (HHS), the FDA, and the Federal Trade Commission, the groups contended that a failure to act "is tantamount to a license to Reynolds and other tobacco companies to make unsubstantiated and unproven health claims with impunity and without fear of federal oversight."

In their letter to HHS Secretary Tommy Thompson, the health organizations cited a recent report by the Institute of Medicine, which concluded that none of the so-called reduced risk tobacco products have proven less hazardous than standard cigarettes.

Eclipse uses a charcoal heat source containing a small amount of tobacco at its tip, which burns. The heat from the burning tip passes through a length of tobacco, which doesn’t burn, and glycerin, which vaporizes. The result is smoke and flavor reaching the smoker.

R.J. Reynolds has claimed that Eclipse has 80% fewer carcinogens in its smoke than do ultralight cigarettes. It currently markets Eclipse in several sections of the country.

Recent Videos
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content